P.V. Carpine Liquifilm en es it fr

P.V. Carpine Liquifilm Brand names, P.V. Carpine Liquifilm Analogs

P.V. Carpine Liquifilm Brand Names Mixture

  • E-Pilo 1 Ophthalmic Solution (Epinephrine bitartrate + Pilocarpine hydrochloride)
  • E-Pilo 2 Ophthalmic Solution (Epinephrine bitartrate + Pilocarpine hydrochloride)
  • E-Pilo 4 Ophthalmic Solution (Epinephrine Bitartrate + Pilocarpine Hydrochloride)
  • E-Pilo 6 Ophthalmic Solution (Epinephrine Bitartrate + Pilocarpine Hydrochloride)
  • E-Pilo-1 Oph Soln (Epinephrine Bitartrate + Pilocarpine Hydrochloride)
  • E-Pilo-2 Oph Soln (Epinephrine Bitartrate + Pilocarpine Hydrochloride)
  • E-Pilo-4 Oph Soln (Epinephrine Bitartrate + Pilocarpine Hydrochloride)
  • E-Pilo-6 Oph Soln (Epinephrine Bitartrate + Pilocarpine Hydrochloride)
  • Timpilo 2 (Pilocarpine Hydrochloride + Timolol Maleate)
  • Timpilo 4 (Pilocarpine Hydrochloride + Timolol Maleate)

P.V. Carpine Liquifilm Chemical_Formula

C11H16N2O2

P.V. Carpine Liquifilm RX_link

http://www.rxlist.com/cgi/generic3/salagen.htm

P.V. Carpine Liquifilm fda sheet

P.V._Carpine_Liquifilm FDA

P.V. Carpine Liquifilm msds (material safety sheet)

P.V._Carpine_Liquifilm MSDS

P.V. Carpine Liquifilm Synthesis Reference

Preobrashenski et al., Ber. 66, 1187 (1933)

P.V. Carpine Liquifilm Molecular Weight

208.257 g/mol

P.V. Carpine Liquifilm Melting Point

34 oC

P.V. Carpine Liquifilm H2O Solubility

1000 mg/ml

P.V. Carpine Liquifilm State

Solid

P.V. Carpine Liquifilm LogP

1.02

P.V. Carpine Liquifilm Dosage Forms

Drops; Gel; Implant; Liquid; Solution

P.V. Carpine Liquifilm Indication

For the treatment of radiation-induced dry mouth (xerostomia) and symptoms of dry mouth in patients with Sjögrens syndrome.

P.V. Carpine Liquifilm Pharmacology

Pilocarpine is a choline ester miotic and a positively charged quaternary ammonium compound. Pilocarpine, in appropriate dosage, can increase secretion by the exocrine glands. The sweat, salivary, lacrimal, gastric, pancreatic, and intestinal glands and the mucous cells of the respiratory tract may be stimulated. When applied topically to the eye as a single dose it causes miosis, spasm of accommodation, and may cause a transitory rise in intraocular pressure followed by a more persistent fall. Dose-related smooth muscle stimulation of the intestinal tract may cause increased tone, increased motility, spasm, and tenesmus. Bronchial smooth muscle tone may increase. The tone and motility of urinary tract, gallbladder, and biliary duct smooth muscle may be enhanced. Pilocarpine may have paradoxical effects on the cardiovascular system. The expected effect of a muscarinic agonist is vasodepression, but administration of pilocarpine may produce hypertension after a brief episode of hypotension. Bradycardia and tachycardia have both been reported with use of pilocarpine.

P.V. Carpine Liquifilm Absorption

There was a decrease in the rate of absorption of pilocarpine from SALAGEN Tablets when taken with a high fat meal by 12 healthy male volunteers

P.V. Carpine Liquifilm side effects and Toxicity

No information avaliable

P.V. Carpine Liquifilm Patient Information

Patients should be informed that pilocarpine may cause visual disturbances, especially at night, that could impair their ability to drive safely.

If a patient sweats excessively while taking pilocarpine hydrochloride and cannot drink enough liquid, the patient should consult a physician. Dehydration may develop.

P.V. Carpine Liquifilm Organisms Affected

Humans and other mammals